- Home
- UTHR vs PNR Comparison
UTHR vs PNR Comparison
Compare UTHR & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- PNR
- Stock Information
- Founded
- UTHR 1996
- PNR 1966
- Country
- UTHR United States
- PNR United Kingdom
- Employees
- UTHR N/A
- PNR N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- PNR Industrial Machinery/Components
- Sector
- UTHR Health Care
- PNR Industrials
- Exchange
- UTHR Nasdaq
- PNR Nasdaq
- Market Cap
- UTHR 14.4B
- PNR 13.3B
- IPO Year
- UTHR 1999
- PNR N/A
- Fundamental
- Price
- UTHR $308.00
- PNR $93.54
- Analyst Decision
- UTHR Buy
- PNR Buy
- Analyst Count
- UTHR 12
- PNR 16
- Target Price
- UTHR $392.00
- PNR $107.33
- AVG Volume (30 Days)
- UTHR 439.7K
- PNR 1.6M
- Earning Date
- UTHR 04-30-2025
- PNR 04-22-2025
- Dividend Yield
- UTHR N/A
- PNR 1.07%
- EPS Growth
- UTHR 18.86
- PNR 2.96
- EPS
- UTHR 25.10
- PNR 3.87
- Revenue
- UTHR $2,994,100,000.00
- PNR $4,076,000,000.00
- Revenue This Year
- UTHR $11.45
- PNR $2.16
- Revenue Next Year
- UTHR $6.11
- PNR $3.88
- P/E Ratio
- UTHR $12.27
- PNR $24.17
- Revenue Growth
- UTHR 19.84
- PNR N/A
- 52 Week Low
- UTHR $260.41
- PNR $72.63
- 52 Week High
- UTHR $417.82
- PNR $110.71
- Technical
- Relative Strength Index (RSI)
- UTHR 57.25
- PNR 63.28
- Support Level
- UTHR $290.02
- PNR $91.18
- Resistance Level
- UTHR $319.40
- PNR $93.71
- Average True Range (ATR)
- UTHR 10.02
- PNR 2.23
- MACD
- UTHR 2.72
- PNR 0.82
- Stochastic Oscillator
- UTHR 69.99
- PNR 93.50
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About PNR Pentair plc.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Pentair's business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.1 billion in revenue in 2024.